Abfero Pharmaceuticals Inc. is a clinical stage pharmaceutical company based in Lexington, MA, dedicated to developing best-in-class oral iron chelators for the treatment of diseases of iron overload. Their lead candidate, SP-420, is a brain-penetrant small molecule that shows promise in addressing iron accumulation in the retina and brain, which is associated with retinal and neurologic diseases leading to vision loss and neurodegeneration.
With a focus on both systemic iron overload due to transfusions and local iron overload, Abfero Pharmaceuticals aims to meet the urgent need for effective, safe, and tolerable treatments for these conditions. Their small molecule technology and clinical stage pipeline are driven by the growing population of aging patients and the rising prevalence of age-related macular degeneration, the leading cause of irreversible blindness in the United States.
Generated from the website